ATE447587T1 - Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen - Google Patents

Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Info

Publication number
ATE447587T1
ATE447587T1 AT04811735T AT04811735T ATE447587T1 AT E447587 T1 ATE447587 T1 AT E447587T1 AT 04811735 T AT04811735 T AT 04811735T AT 04811735 T AT04811735 T AT 04811735T AT E447587 T1 ATE447587 T1 AT E447587T1
Authority
AT
Austria
Prior art keywords
inflammation
antibodies
binding partners
pta
atcc
Prior art date
Application number
AT04811735T
Other languages
German (de)
English (en)
Inventor
Wenfeng Xu
Wayne Kindsvogel
Zhi Chen
Steven Hughes
Yasmin Chandrasekher
Stacey Dillon
Joyce Lehner
Anthony Siadak
Pallavur Sivakumar
Margaret Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE447587T1 publication Critical patent/ATE447587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04811735T 2003-11-21 2004-11-19 Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen ATE447587T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52413103P 2003-11-21 2003-11-21
US55585704P 2004-03-24 2004-03-24
PCT/US2004/039071 WO2005052000A2 (en) 2003-11-21 2004-11-19 Anti-il-20 antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
ATE447587T1 true ATE447587T1 (de) 2009-11-15

Family

ID=34636508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04811735T ATE447587T1 (de) 2003-11-21 2004-11-19 Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Country Status (8)

Country Link
US (3) US20050170468A1 (enExample)
EP (3) EP1697418A2 (enExample)
JP (3) JP4991307B2 (enExample)
AT (1) ATE447587T1 (enExample)
CA (2) CA2545867A1 (enExample)
DE (1) DE602004023965D1 (enExample)
ES (1) ES2334140T3 (enExample)
WO (2) WO2005052000A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
MXPA05010134A (es) * 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion.
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
CA2596390A1 (en) * 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
US7611705B2 (en) * 2007-06-15 2009-11-03 National Cheng Kung University Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases
AU2009265808B2 (en) 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
US7837994B2 (en) * 2008-10-07 2010-11-23 National Cheng Kung University Use of anti-IL-20 antibody for treating osteoporosis
US8012478B2 (en) * 2008-10-07 2011-09-06 National Cheng Kung University Use of anti-IL-20 antibody for treating stroke
EP2340039B1 (en) * 2008-10-07 2015-11-25 National Cheng Kung University Use of il-20 antagonists for treating osteoporosis
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CA2796064A1 (en) * 2010-04-16 2011-10-20 National Cheng Kung University Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity
US8535674B2 (en) 2010-06-15 2013-09-17 National Cheng Kung University Treating breast cancer and inhibiting cancer-associated bone loss with anti-IL-20 antibody
EP2812445A2 (en) 2012-02-10 2014-12-17 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) * 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
KR102216949B1 (ko) * 2012-12-14 2021-02-22 민데라 코포레이션 바이오마커의 검출 및 취득을 위한 방법 및 디바이스
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
CN106132920A (zh) 2014-04-04 2016-11-16 沙特基础工业全球技术有限公司 最小化乙醇胺产物流股中的水含量
EP3129349A1 (en) 2014-04-08 2017-02-15 SABIC Global Technologies B.V. Minimizing water content in ethanolamine product streams
CN106458848A (zh) 2014-05-27 2017-02-22 沙特基础工业全球技术有限公司 不存在与纯剪切的dea 99%混合的情况下直接生产tea 85%
WO2015181751A1 (en) 2014-05-30 2015-12-03 Sabic Global Technologies B.V. Improved quality and color of ethanolamine product streams by reduced temperature at the triethanolamine column
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
AU2015282844A1 (en) * 2014-07-03 2016-12-15 Immunoqure Ag Human-derived anti-human IL-20 antibodies and assay for the identification of anti-cytokine antibodies
CN107743586B (zh) 2015-06-03 2021-07-02 百时美施贵宝公司 用于癌症诊断的抗gitr抗体
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
EP3464357A1 (en) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
US9982043B2 (en) * 2016-06-03 2018-05-29 National Cheng Kung University Use of IL-20 antagonists for treating pancreatic cancer
US20180057564A1 (en) * 2016-08-23 2018-03-01 Clover Biopharmaceuticals Antagonists of il-20 family of cytokines and their use
JP7274426B2 (ja) 2017-05-16 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP7258329B2 (ja) * 2018-09-01 2023-04-17 国立大学法人神戸大学 連続式振動流バッフル反応装置及び反応法
EP4025604A1 (en) * 2019-09-04 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies specific for il20-rb and uses thereof for the treatment of acute exacerbation of chronic obstructive pulmonary disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5436155A (en) 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
GB2315386B (en) 1996-07-13 2000-10-18 Motorola Ltd Improved flow control in cellular radio networks
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
JP2001500369A (ja) 1996-08-30 2001-01-16 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド インターロイキン―１９
DE19650541C2 (de) 1996-12-05 1999-05-12 Siemens Ag Verfahren zur Ermittlung eines ersten Referenzschriftzugs anhand mehrerer Musterschriftzüge
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
WO1998048837A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
EP1012260A4 (en) 1997-07-16 2001-05-09 Human Genome Sciences Inc INTERLEUKINE-20
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6020163A (en) 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
CN1618969A (zh) * 1997-11-26 2005-05-25 津莫吉尼蒂克斯公司 哺乳动物细胞因子样多肽－10
PT1047781E (pt) 1998-01-23 2004-11-30 Immunex Corp Receptores de il-18
US6586228B1 (en) 1998-03-09 2003-07-01 Schering Corporation Polynucleotides encoding DIRS1
EP1062332A2 (en) 1998-03-09 2000-12-27 Schering Corporation Human receptor proteins; related reagents and methods
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
AU2150000A (en) 1998-11-25 2000-06-13 Zymogenetics Inc. Zace1: a human metalloenzyme
AU2222700A (en) 1998-12-31 2000-07-31 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
WO2000073457A1 (en) 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6897292B2 (en) 1999-12-03 2005-05-24 Zymogenetics, Inc. Human cytokine receptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ATE459369T1 (de) * 1999-12-23 2010-03-15 Zymogenetics Inc Verfahren zur behandlung von entzündungen
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ES2267814T3 (es) * 2000-09-15 2007-03-16 Zymogenetics, Inc. Metodo para tratar la inflamacion.
EP1390060A2 (en) 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
CA2433933A1 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
AU2002245652A1 (en) 2001-03-09 2002-09-24 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
IL161978A0 (en) 2001-12-17 2005-11-20 Zymogenetics Inc Method for treating cervical cancer
JP4504023B2 (ja) 2002-03-22 2010-07-14 ザイモジェネティクス インコーポレーティッド 抗ｉｌ−ｔｉｆ抗体および炎症において使用する方法
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP4053444B2 (ja) * 2003-03-07 2008-02-27 シャープ株式会社 携帯可能な多機能電子機器
MXPA05010134A (es) 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion.
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
JP2008106946A (ja) * 2005-02-10 2008-05-08 Matsushita Electric Ind Co Ltd 冷凍サイクル装置
MY161894A (en) * 2006-09-08 2017-05-15 Abbvie Bahamas Ltd Interleukin-13 binding proteins
AU2009265808B2 (en) * 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies

Also Published As

Publication number Publication date
JP2007537993A (ja) 2007-12-27
DE602004023965D1 (de) 2009-12-17
US7393684B2 (en) 2008-07-01
US8907068B2 (en) 2014-12-09
CA2542546A1 (en) 2005-06-09
JP2007535490A (ja) 2007-12-06
WO2005052001A2 (en) 2005-06-09
US20080247945A1 (en) 2008-10-09
WO2005052001A3 (en) 2005-08-04
EP1692180A2 (en) 2006-08-23
JP4991307B2 (ja) 2012-08-01
EP1692180B1 (en) 2009-11-04
ES2334140T3 (es) 2010-03-05
EP1697418A2 (en) 2006-09-06
CA2545867A1 (en) 2005-06-09
JP2012036204A (ja) 2012-02-23
WO2005052000A2 (en) 2005-06-09
US20050170468A1 (en) 2005-08-04
EP2143733A1 (en) 2010-01-13
US20050136004A1 (en) 2005-06-23
WO2005052000A3 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
ATE447587T1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
TW200635945A (en) Antibodies against IL-13 receptor alpha 1 and uses thereof
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ATE501170T1 (de) Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
ATE265531T1 (de) Verfahren zur herstellung modifizierter immunoglobulinen mit reduzierter immunogenität der variablen domänen einer murinen antikörpers, zusammensetzungen die diese enthalten
NZ547157A (en) Interferon Alpha Antibodies and their uses
ATE402267T1 (de) Verfahren zur herstellung von monoklonalen antikörpern
ATE366747T1 (de) Menschliche monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor
NZ529612A (en) Anti-NGF antibodies for the treatment of various disorders
MXPA03009776A (es) Inmunoglobulina 2.
SI2481753T1 (en) Anti-IL-17 antibodies
EP1362868A3 (en) Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
NZ614727A (en) Human antibodies that bind human tnfa
DE69830901D1 (de) ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP2186884A3 (en) HCV-anti-core monoclonal antibody
IL139419A0 (en) Monoclonal antibodies, cross-reactive antibodies and method for producing the same
EP2261253A3 (en) Antibodies directed to Clostridium difficile
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE69504620D1 (de) Monoklonaler Antikörper gegen menschliches Glicentin, Hybridoma zur Herstellung dieses Antikörpers und Testverfahren für menschliches Glicentin unter Verwendung dieses Antikörpers
ATE337395T1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
WO2004029069A3 (en) Hybridomas producing high levels of human sequence antibody

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1692180

Country of ref document: EP